How the sialylation level of serum N-acetyl-beta-D-glucosaminidase A form in Type 1 diabetes mellitus influences their activity? by Jovanović, Vesna B. et al.
  
J. Serb. Chem. Soc. 79 (12) 1491–1503 (2014) UDC 547.455.623’292:54.05+ 
JSCS–4682 577.15:616.379–008.64 
 Original scientific paper 
1491 
How the sialylation level of serum N-acetyl-β-D-glucosaminidase 
A form in Type 1 diabetes mellitus influences their activity? 
VESNA B. JOVANOVIĆ1#, JELENA M. AĆIMOVIĆ1#, VESNA S. DIMITRIJEVIĆ 
SREĆKOVIĆ2 and LJUBA M. MANDIĆ1*# 
1Faculty of Chemistry, Chair of Biochemistry, University of Belgrade, Studentski trg 12–16, 
Belgrade 11158, Serbia and 2Institute of Endocrinology, Diabetes and Metabolic Diseases, 
Clinical Center of Serbia, Belgrade 11000, Dr Subotića 13, Serbia 
(Received 30 April, revised 9 July, accepted 17 July 2014) 
Abstract: It was verified that the serum N-acetyl-β-D-glucosaminidase (NAG) 
activity is elevated in diabetes, but there are no reports about changes in the 
sialic acid (SA) content in the carbohydrate parts of the NAG A form and its 
influence on the total changes in NAG activity in type 1 diabetes mellitus 
patients with and without secondary complications. The NAG A form was iso-
lated from the serum of 81 insulin-dependent diabetes mellitus (IDDM) 
patients with and without secondary complications (retinopathy, polyneuro-
pathy and nephropathy) and 25 healthy persons, and purified and characterised. 
The content of α-2,6-bound SA, the isoenzyme patterns of the purified A form, 
and the total NAG and A form activities were determined. In all diabetic 
groups, the sialylation levels of the A form were 2–3.5 times lower compared 
to control, while their acidities (fractions with pI 4.25–5.1) increased, particul-
arly with progression of secondary complications. Total serum NAG activities 
and percentages of A form were significantly higher (P < 0.001) in all diabetic 
groups and negatively correlated with the α-2,6-bound SA content of the A 
form. In addition, they decreased as secondary diabetic complications became 
more complex. The observed changes could be the consequence of structural 
changes in the A form due to significant increases in its acidity, i.e., negative 
charge, which originated from groups other than SA. 
Keywords: N-acetyl-β-D-glucosaminidase; A isoenzyme isolation and char-
acterization; sialylation level, diabetes mellitus type 1; secondary compli-
cations. 
INTRODUCTION 
The serum N-acetyl-β-D-glucosaminidase (NAG, EC 3.2.1.52) activity and 
sialic acid (SA) are elevated in individuals diagnosed with diabetes mellitus1–3 
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and diabetic complications.4–6 NAG is a lysosomal enzyme that is involved in 
the degradation of the oligosaccharide chains of glycoproteins, glycolipids and 
glycosaminoglycans. All serum NAG isoenzymes are glycoproteins that can be 
separated into two major isoenzymes, A and B, and several minor isoenzymes (I, 
P and S). They derive from different combinations of two polypeptide chains, α- 
and β-subunits, with additional heterogeneity conferred by posttranslational mod-
ifications. Among them carbohydrate part of NAG A contains the highest level of 
SA, which significantly contributes to the overall negative charge of its mole-
cules. Therefore, NAG A has the lowest isoelectric point (its pI is close to 5).7 In 
addition, SA may contribute to the stability and survival of glycoproteins (e.g., 
NAG) in blood circulation.8 Many reasons for the increase in serum NAG 
activity in diabetics have been proposed, such as poor glycemic control;9 the gly-
comaterial deposits on blood vessels; long-term disruption of metabolic equilib-
rium in diabetics with an alleviated release of lysosomal enzymes, especially the 
A form,10 into the extracellular liquid, which interferes with the mechanisms 
controlling the half-life of enzymes.11 However, none of these explanations have 
been fully elucidated. 
Increased NAG exocytosis, i.e., the redistribution of the percentage of sec-
reted enzyme compared to the percentage transported to lysosome, as well as 
changes in the activity and half-life of serum NAG could result from posttrans-
lational modifications of enzymes (changes in the SA content in their carbohyd-
rate components) in patients with hyperglycaemia. To the best of our knowledge, 
there are no reports that examine the changes in the carbohydrate components of 
NAG isoenzymes in diabetic patients with various secondary complications. To 
gain insight into these changes, the NAG A form from the serum of patients with 
insulin-dependent diabetes mellitus (IDDM) with and without various secondary 
complications was isolated and characterized, and the SA in the carbohydrate 
components of the A forms was analyzed and their correlation with changes in 
the total NAG activity examined. In this study, for the first time, the reduced 
sialylation levels of the A form from patients with IDDM is reported. However, 
the acidity of the A form (negative charge) increased as the diabetic complica-
tions progressed. These findings provide a deeper understanding of the changes 
in NAG activity in diabetics compared to healthy individuals and between groups 
of patients with IDDM. 
EXPERIMENTAL 
Subjects 
Eighty-one patients with IDDM were grouped according to the following secondary 
complications:10 without complications (W.Compl., n = 24); with retinopathy (R, n = 19); 
with retinopathy and polyneuropathy (R+P, n = 18); and with retinopathy, polyneuropathy and 
nephropathy (R+P+N, n = 20). The characteristics of these patients are listed in Table I. The 
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control group consisted of 25 healthy volunteers of appropriate ages and sex. This study was 
approved by the institutional ethics committee on human research. 
TABLE I. Clinical and biochemical characteristics of the control group and groups of patients 
with IDDM; W.Compl. – without complications, R – with retinopathy, R+P – with retino-
pathy and polyneuropathy, R+P+N – with retinopathy, polyneuropathy and nephropathy. The 
values are expressed as the mean ± standard deviation (SD). aP < 0.001, bP < 0.01, cP < 0.05 
compared with the control group. dP < 0.001, eP < 0.05 compared with W.Compl. fP < 0.001, 
gP < 0.01, hP < 0.05 compared with R. iP < 0.001, jP < 0.01, kP < 0.05 compared with R+P. 
SBP, systolic blood pressure; DBP, diastolic blood pressure 
Characteristic Control group W.Compl. R R+P R+P+N 
n (M/F) 25 (11/14) 24 (12/12) 19 (7/12) 18 (11/7) 20 (9/11) 
Age, y 30.2±8.7 24.6±7.4 26.2±2.2 33.8±14.8 31.2±10.1 
Diabetes duration, y – 6.6±5.5 14.8±5.5d 15.1±11d 18.3±9.4d 
SBP / mmHg 109±9 115±8c 119±5a,e 122±7b,e 132±9a,d,g 
DBP / mmHg 83±6 77±6 83±5 80±7 88±6 
Glucose concen-
tration, mmol L-1 
4.8±0.5 11.5±2.9a 14.3±2.6a,e,j 9.0±2.9a 12.9±3.1a,k 
HbA1c, % 4.9±0.5 9.3±0.8a 11.1±0.9a 10.1±1.4a 10.1±0.5a 
Albuminuria,  
mg per 24 h 
13.34±6.1 18.12±5.40 15.32±7.2 10.25±3.5 192.5±99.5a,d,f,i 
Proteinuria, g L-1 – – – – 1.09±0.73 
NAG activity, IU L-1 3.19±0.5a 4.54±1.15a 5.72±1.06a,e 5.44±0.92a 5.08±2.05a 
A form, % 69.38±4.98 83.82±5.82a 84.48±5.2a 81.9±5.24a 76.22±7.42a,e,k 
Chemicals and instrumentation 
All chemicals that were used were of analytical grade and were purchased from Merck 
(Darmstadt, Germany) and Sigma–Aldrich (Steinheim, Germany). Con A-Sepharose 4B and 
Sephadex G-100 were obtained from GE Healthcare (Uppsala, Sweden). SNA-HRPO was 
purchased from MyBioSource (San Diego, CA, USA). Spectrophotometric measurements 
were performed using a Beckman DU-50 spectrophotometer (Fullerton, USA) and an LKB 
5060-066 microplate reader (Uppsala, Sweden). 
Serum samples 
Blood samples were collected after the patients had fasted overnight between 07:00 pm 
and 07:30 am.  
Biochemical methods 
Using 2-methoxy-4-(2-nitrovinyl)phenyl-2-(acetylamine)-2-deoxy-β-D-glucopyranoside, 
the activity of NAG was determined as previously described.10 A unit of enzymatic activity 
(IU) was defined as the amount of enzyme used to hydrolyse 1 μmol of substrate in one minute 
at 37 °C (IU L-1 = μmol min L-1). The intra- and inter-assay variations of the measurements of 
total NAG activity were 1.8 and 3.2 %, respectively. 
The fasting serum glucose, glycated haemoglobin (HbA1c) and microalbuminuria were 
determined with a Hitachi 912 autoanalyser using commercial kits (Randox, Crumlin, UK). 
The content of proteins was determined by the Bradford method.12 
Isoelectrofocusing and native polyacrylamide gel electrophoresis (PAGE) were per-
formed according to the manufacturers’ recommendations using a Multiphor® II electropho-
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resis system (Pharmacia BioTech Ltd., Little Chalfont, Buckinghamshire, UK) and a Hoefer® 
SE 260 electrophoretic unit (San Francisco, CA, USA), respectively. The enzyme activity was 
determined by dividing the polyacrylamide gels into sections (3 mm×5 mm) and incubating 
each section with substrate at 37 °C for 24 h. 
Isolation and purification of the serum NAG A isoenzyme  
Ion-exchange chromatography on DEAE cellulose column was used to separate the NAG 
isoenzyme forms from fresh serum (4–6 mL) of each person from the control and the IDDM 
groups. Prior to the chromatography, the serum was dialysed overnight against 0.01 mol L-1 of 
phosphate buffer, pH 7.0, at 4 °C. The B form was eluted with 0.01 mol L-1 phosphate buffer, 
pH 7.0. The A form was isolated using a linear concentration gradient (0–0.3 mol L-1) of 
sodium chloride in the same buffer. Fractions containing 90 % of the total A isoenzyme acti-
vity were pooled according to the groups, concentrated by ultrafiltration (PM-30; Amicon) 
and stored at –20ºC. 
Gel chromatography. All pooled solutions of the isolated A isoenzyme were dialysed 
overnight at 4 °C against 0.05 mol L-1 phosphate buffer containing 0.15 mol L-1 sodium 
chloride, pH 7.0 and applied to a Sephadex G-100 column. The enzyme was eluted with the 
same buffer. Fractions containing 35–50 % of the total eluted A isoenzyme activity were 
pooled, concentrated by ultrafiltration and dialysed overnight at 4 °C against 20 mmol L-1 of 
2-amino-2-(hydroxymethyl)propane-1,3-diol (Tris) buffer, pH 7.0, containing 1 mmol L-1 
manganese(II) chloride, 1 mmol L-1 calcium chloride and 0.5 mmol L-1 sodium chloride 
(wash buffer). 
Affinity chromatography. The dialysed solution was then applied to a Concanavalin 
A-Sepharose 4B column equilibrated with wash buffer. The enzyme was eluted with 0.5 mol 
L-1 α-methyl-D-mannoside dissolved in wash buffer. The two fractions with the highest 
enzyme activity were pooled and stored at –20 °C for electrophoresis, isoelectrofocusing and 
enzyme-linked lectin binding assays.  
Enzyme-linked lectin binding assays (ELBAs) 
The ELBAs were performed in 96-well microtitre plates (Nunc, Roskilde, Denmark) 
coated overnight at 4 °C with 200 µL of fetuin (0.01 mg mL-1) or BSA (0.01 mg mL-1) 
solution in 0.025 mmol L-1 phosphate buffer, pH 7.4, containing 0.15 mol L-1 sodium chloride 
(PBS) per well. The plates were then washed once with 200 µL of PBS/0.05 % (V/V) Tween 
20 buffer (PBS-T) and blocked with 200 µL of 1 % BSA dissolved in PBS-T buffer at room 
temperature for 1 h. After blocking, the wells were washed twice with 200 µL of PBS-T 
buffer and then 75 µL of the purified A isoenzyme of serum NAG (starting protein concen-
tration of 1 mg mL-1 that was serially diluted in PBS-T) of the control and IDDM patients and 
75 µL of SNA conjugated with HRPO (diluted 1:5000 in assay buffer) were added. After 
incubation in the dark at room temperature for 2 h, the wells were washed twice with 200 µL 
of PBS-T buffer.  
The spectrophotometric determination of the binding HRPO activity per well was per-
formed by mixing 100 μL of urea–hydrogen peroxide (1.8 mg mL-1) and 100 μL of TMB (1.4 
mg mL-1). After 10 min at room temperature, 50 μL of sulphuric acid (2 mol L-1) was added, 
and the absorbance at 450 nm was measured. All sample dilutions were analysed in triplicate 
in two repeated experiments. 
The reactivity of the A form of serum NAG with SNA lectin (binding SA) in the ELBA 
system was expressed as the concentration of the A form of NAG (in μg mL-1), which led to 
50 % inhibition of SNA linking to immobilised fetuin. 
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The procedures and experiments were in accordance with the ethical standards of the 
responsible committee on human experimentation (institutional and national) and with the 
Helsinki Declaration of 1975, as revised in 2000. 
Statistical analysis 
The Student’s t-test, linear regression analysis and Pearson’s correlation coefficient were 
used to analyse the data. Only values in which P < 0.05 were considered to be significant. 
RESULTS 
In all IDDM groups (W.Compl., R, R+P and R+P+N), the mean values of 
total NAG activity and percentage of the dominant A form (Table I) in serum 
were significantly higher (P < 0.001) compared to those of the control group 
(3.19±0.5 IU L–1 and 69.38±4.98 %, respectively). Significant positive correl-
ations were obtained (0.945, 0.943, 0.940 and 0.963, respectively; P < 0.001) by 
comparing these two parameters as well as the activity of the A form of NAG 
and glycaemia (0.511, 0.537, 0.609 and 0.568, respectively; P < 0.05). 
During the separation of the NAG isoenzymes from the serum of the control 
and IDDM groups by ion-exchange chromatography, a difference in the bonding 
strength between the A form and DEAE-cellulose was observed (Fig. 1). Addi-
tionally, the A isoenzyme of patients with R+P+N was eluted with a slightly 
higher concentration ((6.95±0.89)×10–2 mol L–1) of sodium chloride compared 
to those of the other three diabetic groups. However, the mean values of the 
sodium chloride concentration used to elute 50 % of the serum A isoenzyme 
activity of the control and diabetic groups did not differ statistically (Table II). 
Fig. 1. NAG isoenzyme profiles of 
the control and IDDM groups 
obtained by ion-exchange chroma-
tography on DEAE cellulose. The 
sodium chloride gradient from 0 to 
0.3 mol L-1 was introduced after 54 
mL of eluate. 
To determine the origin of the increased negative charge of NAG A in dia-
betics, the isoenzymes of NAG A were isolated and purified from the serum of 
the control and all diabetic groups. In all groups, the A form was purified 180- to  
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TABLE II. Mean values of NaCl concentration (in 0.01 M of phosphate buffer, pH 7.0) used 
to elute 50 % of the NAG A isoenzyme from the DEAE-cellulose column from the serum of 
the control and IDDM groups; W.Compl. – without complications; R – with retinopathy; R+P 
– with retinopathy and polyneuropathy; R+P+N – with retinopathy, polyneuropathy and 
nephropathy 
Group cNaCl / 10-2 mol L-1 
Control 6.37±0.37 
W.Compl. 6.35±0.62 
R 6.35±0.72 
R+P 6.40±0.51 
R+P+N 6.95±0.89 
200-fold, yielding 10.8–16 % of enzyme (Table III). The purity of the isolated A 
forms was analysed by native PAGE electrophoresis (Fig. 2), whereby one domi-
nant band was observed. This band was derived from the A form of NAG (mole-
cular mass of 120 kDa),13 which was confirmed by determination of enzyme 
activity in the gel slice. The relative electrophoretic mobility (REM) of the A 
form gradually increased with progression of diabetic complications (Table III), 
indicating a slight increase in the acidity of the A form. 
TABLE III. Purification – fold, yield, % and relative electrophoretic mobilities (REM) 
obtained by native PAGE of the A form isolated and purified from the serum of the control 
and IDDM groups; W.Compl. – without complications; R – with retinopathy; R+P – with 
retinopathy and polyneuropathy; R+P+N – with retinopathy, polyneuropathy and nephropathy 
Line Group Purification – fold Yield, % REM 
1 Control 200 11 0.560±0.018 
2 W.Compl. 195 16 0.582±0.020 
3 R 180 10.8 0.619±0.024 
4 R+P 190 12 0.629±0.022 
5 R+P+N 185 13 0.639±0.027 
Fig. 2. Native PAGE of purified serum NAG A 
form from control (lane 1) and IDDM groups (lane 
2, W.Compl.; lane 3, R; lane 4, R+P; lane 5, 
R+P+N) showing the changes in mobility of the A 
form. The electrophoresis was performed on 9 % 
polyacrylamide gels and the protein bands were 
visualised by Coomassie Brilliant Blue (CBB). 
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Significant differences in the distribution of the A form fraction between the 
control group and IDDM patients with secondary complications were observed 
by isoelectrofocusing (Fig. 3A). In the IDDM group, apart from the dominant A 
isoenzyme fraction (pI value approximately 5.6; pI range 5.1–6.0), more acidic 
fractions were observed (pI values in the range 4.25–5.10, Fig. 3B). Using den-
sitometry, the percentage of these fractions (pI 4.25–5.10) was found to increase 
with the progression of secondary complications, so that they were 2–4 times 
higher compared to that of the control group (Table IV). In the R+P+N group, the 
percentage of this fraction was reached 51.5±1.8 %. 
   
 (A) (B) 
Fig. 3. A) IEF (linear gel of pH 3–10) of purified A form from the serum of the control 
(lane 1) and IDDM groups (lane 2, W.Compl; lane 3, R; lane 4, R+P; lane 5, R+P+N). 
B) Densitometry of NAG A forms from the serum of the control a) and IDDM groups: 
b), c), d) and e). B.L., base line in the determination of the abundance of the more 
acidic fractions of the A form. 
TABLE IV. Percentage of the more acidic fractions (pI in the range 4.25–5.1) of the A form in 
the control group and the groups of patients with IDDM; The data presented are mean values 
from three experiments ± SD; W.Compl. – without complications; R – with retinopathy; R+P 
– with retinopathy and polyneuropathy; R+P+N – with retinopathy, polyneuropathy and 
nephropathy 
Group More acidic fractions of A form, % 
Control 12.8±0.2 
W.Compl 10.1±0.7 
R 35.1±2.2 
R+P 28.8±1.8 
R+P+N 51.5±1.8 
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The SA content in the carbohydrate parts of isolated A isoenzymes from the 
serum of control and IDDM groups (Table V) was analysed using ELBA, which 
is based on the competitive binding of NAG and fetuin (an immobilised glyco-
protein ligand) to SNA lectin (specific for terminally α-2,6-bound SA) con-
jugated with HRPO. The A form from the serum of the control group exhibited 
the highest inhibitory effect on SNA binding to fetuin (i.e., the highest α-2,6- 
-bound SA content). In the case of the A isoenzyme from the serum of all IDDM 
groups, to achieve 50 % inhibition of SNA binding to fetuin, 2–3.5 times higher 
concentrations of the A form were required compared to that of the control 
group. Thus, the A forms in diabetic groups were less sialylated compared to 
those of the control group. Furthermore, comparisons between diabetic groups 
showed that the lowest and highest sialylation levels of the A form were obs-
erved in the R and R+P+N groups, respectively. 
TABLE V. Content of α-2,6-bound SA in the isolated and purified A isoenzymes from the 
serum of the control group and patients with IDDM, which was estimated based on the 
concentration, μg mL-1, of the serum A form leading to 50 % inhibition of SNA binding to 
fetuin. All measurements were performed in triplicate, in two repeated experiments, and are 
presented as mean ± SD; W.Compl. – without complications; R – with retinopathy; R+P – 
with retinopathy and polyneuropathy; R+P+N – with retinopathy, polyneuropathy and 
nephropathy 
Group c(A form) / μg mL-1, leading to 50 % inhibition 
Control 18.99±0.84 
W.Compl. 54.54±1.52 
R 62.52±1.70 
R+P 42.20±1.84 
R+P+N 32.13±0.91 
An overview of the changes in the total serum NAG activity, the contri-
bution of the A isoenzyme activity in the total NAG activity and the NAG A 
isoenzyme α-2,6-bound SA content is presented in Fig. 4. 
DISCUSSION 
In all IDDM groups, the total NAG activity and percentage of the A form 
were significantly higher compared to those of the control group, which is in 
agreement with previously reported data.3,4 Changes in total NAG activity cor-
related with changes in the activity of the A form as diabetic complications 
become more complex (from W.Compl. to R+P+N), which was confirmed by 
the high correlation coefficients (from 0.940 to 0.963) determined between 
these two parameters. Due to the significant positive correlation observed 
between the activity of the serum NAG A form and glycaemia, it was concluded 
that the total NAG activity increased in IDDM patients mainly as a result of the 
increased exocytosis (release into circulation) of the A form in hyperglycaemic pat- 
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Fig. 4. Summary of the changes in the total serum NAG activity (□), contribution of the A 
isoenzyme activity to the total NAG activity (), and NAG A isoenzyme α-2,6-bound SA 
content (●) in the control and IDDM groups, which correspond to the concentration, μg mL-1, 
of the A form leading to 50 % inhibition of SNA binding to fetuin. W.Compl. – without 
complications; R – with retinopathy; R+P – with retinopathy and polyneuropathy; 
R+P+N – with retinopathy, polyneuropathy and nephropathy. 
ients.10 In hyperglycaemics, extracellular glucose passes through the metabolic 
ways independent of insulin, leading to an increase in the flux of N-acetyl-
glucosamine (GlcNAc).14,15 Disturbed glycosaminoglycane metabolism (sub-
stance deposition in the blood vessels of diabetics with complications) and excess 
posttranslational O-glycosylation of proteins with GlcNAc (via O-GlcNAc trans-
ferase) could be involved in the pathogenesis of diabetes and the development of 
secondary complications.16,17 Thus, the increase in O-GlcNAc could result in the 
activation and release of NAG for its removal.18 However, because no statis-
tically significant differences were found between the NAG activities from the 
serum of diabetic groups with various complications, it was concluded that the 
deposition of glycomaterial was not the main reason for the changes in NAG 
activity.10 
Increases in the flux of GlcNAc in diabetics could also cause increased intra-
cellular posttranslational protein modifications,14,15 leading to changes in NAG 
carbohydrate components and NAG distribution inside and outside cells.19 In 
assays of NAG posttranslational modifications in fibroblast cultures, structural 
differences between the NAG carbohydrate components from lysosomes and 
NAG secreted into the medium were established.20 
During ion-exchange chromatography and native PAGE of the serum NAG 
isoenzymes, it was observed that the negative charge of the A form was higher in 
the IDDM groups than in the control group. In the IDDM groups, apart from the 
dominant A isoenzyme fraction (pI value approximately 5.6), more acidic frac-
tions were observed (pI values in the range 4.25–5.1). The percentage of these 
fractions increased 2–4 times with the progression of secondary complications 
compared to that of the control group. In the R+P+N group, the percentage of 
fractions attained 51.5±1.8 %. Considering that NAG α-subunits (only present in 
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the A form) contain oligosaccharide chains with SA as terminal residues21 and 
that changes in the SA content could affect an increase in the acidity of the A 
form, experiments were performed to determine whether there were increases in 
the sialylation levels of NAG in the IDDM groups. 
The obtained results demonstrated that the degree of α-2,6 sialylation of the 
A form in all diabetic groups was lower compared to that in the control group. 
Comparing the diabetic groups, the lowest sialylation level of the A form was 
observed in the R group, whereas the highest was observed in the R+P+N group. 
The reduced intensity of NAG sialylation in diabetics could be a consequence of 
a reduced activity of sialyltransferases or an increased activity of sialidases. In 
the endothelial cells of diabetic rats with hyperglycaemia, the sialidase activity 
was reported to be increased by 78 %, whereas the sialyltransferase activity was 
decreased by 15 %.22,23 On the other hand, an increase in serum neuraminidase6 
and unchanged sialyltransferase activity24 were observed in diabetics. Thus, it is 
assumed that the activation/inhibition ratio of these enzymes in diabetics deter-
mine the sialylation levels of glycoproteins, resulting in the occurrence of various 
sialoforms as well as NAG. The molecular mechanisms of these effects, the 
physiological consequences of the structural and functional changes in molecules 
with modified glycosylation and how these changes are reflected in the develop-
ment of diabetic complications are unknown. Only the effects of modified glyco-
sylation patterns could be observed. The present results showed a reduced con-
tent of α-2,6 bound SA in the IDDM groups. These results also indicated that the 
increased acidity of the A form in the IDDM groups compared to control group 
had another cause. 
In addition to SA, the total negative charge of NAG could also be attributed 
to other negatively charged groups (e.g., phosphate or sulphate). Newly syn-
thesised lysosomal enzymes lack or exhibit reduced levels of mannose-6-phos-
phate residues in their oligosaccharide chains, leading to hypersecretion and 
intracellular deficiency of multiple lysosomal enzymes.25 Thus, NAG, which is 
secreted in higher levels in diabetes, may have a reduced number of phosphate 
groups. A sulphate cap could be added to the end of complex-type carbohydrate 
chains26 or Tyr residues of secretory proteins.27 The sequence within the β-sub-
unit of the A form of serum NAG could be a site for Tyr sulphation.27 Negative 
charges derived from sulphation may contribute to the changes in the structure 
and activity of the A form. Additional studies are required to understand better 
these changes in NAG A. 
How do the changes in the acidity of the NAG A isoenzyme correlate with 
the increased activity of serum NAG in diabetics? Increased serum NAG activity 
in patients with hyperglycaemia could result from an increased rate of exocytosis 
and/or reduced clearance of enzymes. Hyperglycaemia could lead to an increase 
in the exocytosis of lysosomal enzymes through several mechanisms28–36 with 
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NAG packed in secretory vesicles with other secretory products. The clearance of 
lysosomal enzymes from the serum proceeds through the asialoglycoprotein 
(ASGR), mannose and cation-independent mannose 6-phosphate receptors 
(CI-MPR).31–33 The sialylation of the carbohydrate chains of protein masks the 
residues of D-galactose and N-acetyl-D-galactosamine, which are specifically 
recognized by ASGR. The asialo A form of NAG was reported to be rapidly eli-
minated after injection from the circulation of rats.34 The decreased sialylation of 
the A form in all IDDM groups compared to that of the control group should lead 
to the rapid removal of the isoenzyme from the circulation. However, increases in 
the A form and total NAG activities were observed in all diabetic groups (Fig. 4). 
Thus, it could be concluded that the rate of NAG exocytosis in patients with 
hyperglycaemia is higher than that of its clearance. The results obtained in the 
present study could be explained by the number of ASGR in diabetics, which 
drastically decreases on the cell surface.35 The expression of ASGR requires a 
balance between the intracellular concentrations of c-GMP and c-AMP. In dia-
betics, an intracellular increase in c-AMP leads to a decrease in the number of 
ASGRs on the cell surface.36 The decreased number of ASGRs leads to slower 
NAG removal from circulation (i.e., to prolongation of the enzyme half-life), 
increasing the NAG activity in serum if the asialo derivative is active. In accord 
with the present data, Miller et al.20 showed that sialidase action (removal of SA) 
does not alter the activity of the NAG A form. 
Lastly, the changes in total serum NAG activity and A isoenzyme profiles in 
IDDM patients with various secondary complications negatively correlated with 
changes in the SA content (Fig. 4) and negative charges (acidity, in general) of 
the most abundant NAG A form. Due to the presence of a larger number of nega-
tively charged groups (compared to those of SA) on the surface of more than 50 % 
of the A form isolated from the R+P+N group, the activity of the A form is 
reduced, leading to a significantly lower contribution to the total NAG activity 
compared to those of the W.Compl (P < 0.01) and R (P < 0.05) groups. Thus, in 
the diabetic groups, the decrease in total serum NAG activity with the prog-
ression of secondary complications could result from structural changes in the A 
form due to significant increases in the negative charge (acidity, in general). 
Based on the presented results, additional insight into these changes could be 
obtained by investigating the contribution of sulphate and phosphate residues to 
NAG, as well as changes in the activity of other lysosomal enzymes.  
CONCLUSIONS 
The total serum NAG and A isoenzyme activities in IDDM patients were 
negatively correlated with the α-2,6-bound SA content of the NAG A form. In 
this study, for the first time, it was found that patients with IDDM have reduced 
sialylation levels of the A form. However, the acidity of the A form increased in 
IDDM compared to control group. These results indicate that the increase in aci-
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dity of the A form in the IDDM groups has another cause (e.g., the negative 
charge could originate from groups other than SA).  
Abbreviations. NAG, N-acetyl-β-D-glucosaminidase; IDDM, insulin-dependent diabetes 
mellitus; R, retinopathy; P, polyneuropathy; N, nephropathy; BSA, bovine serum albumin; 
TMB, 3,3′5,5′-tetramethylbenzidine; SNA, Sambucus nigra lectin; HRPO, horseradish perox-
idase; ELBA, enzyme-linked lectin binding assay; SD, standard deviation.  
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И З В О Д  
КАКО САДРЖАЈ СИЈАЛИНСКЕ КИСЕЛИНЕ У А-ОБЛИКУ СЕРУМСКЕ 
N-АЦЕТИЛ-β-D-ГЛУКОЗАМИНИДАЗЕ УТИЧЕ НА ЊЕГОВУ АКТИВНОСТ У 
ДИЈАБЕТЕС МЕЛИТУСУ ТИПА 1? 
ВЕСНА Б. ЈОВАНОВИЋ1, ЈЕЛЕНА М. АЋИМОВИЋ1, ВЕСНА С. ДИМИТРИЈЕВИЋ СРЕЋКОВИЋ2 
и ЉУБА М. МАНДИЋ1 
1Хемијски факултет Универзитета у Београду, Катедра за биохемију, Студентски трг 12–16, 11158 
Београд и 2Институт за ендокринологију, дијабетес и болести метаболизма, Клинички центар, 
Др Суботића 13, Београд 
До сада је показано да је активност серумске N-ацетил-β-D-глукозаминидазе (NAG) 
повећана у дијабетесу, али промена садржаја сијалинске киселине (SA) у глико-компо-
ненти A облика NAG и њен утицај на промене у укупној активности NAG код пацијената 
оболелих од дијабетеса типа 1 (IDDM, са секундарним компликацијама и без њих), нису 
разматрани. Стога је А изоензимски облик NAG изолован и пречишћен из серума 81 
IDDM пацијента, са секундарним компликацијама (ретинопатија, полинеуропатија и 
нефропатија) и без њих, и из серума 25 здравих особа, а потом окарактерисан. Одређена 
је укупна активност NAG и активност А обликa, садржај α-2,6 везане SA у пречишћеном 
А облику и профил овог изоензима. Заступљеност α-2,6 везане SA у А облику свих група 
дијабетичара била је 2–3,5 пута мања у поређењу са контролом, док је његова киселост 
(фракције са pI од 4,25 до 5,1) расла, посeбно са напредовањем секундарних компли-
кација. Укупнe активности серумског NAG и процентни удели А облика у укупној актив-
ности били су значајно повишени (P < 0,001) код свих група дијабетичара, и у негативној 
корелацији са садржајем α-2,6 везане SA у А облику. Поред тога, оне су опадале са усло-
жњавањем секундарних компликација. Утврђене промене могу бити последица промене 
структуре A облика услед значајног повећања његове киселости, односно негативне 
шарже која потиче од група које нису остаци SA. 
(Примљено 30. априла, ревидирано 9. јула, прихваћено 17. јула 2014) 
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